To strengthen the development of the Chinese mainland market, Bionime introduce strategic partner - Tonghua Dongbao Pharmaceutical Co., Ltd

Bionime signed a long-term sales contract with Tonghua Dongbao Pharmaceutical Co., Ltd. (Tonghua Dongbao) in August, 2015, and designated Tonghua Dongbao as the exclusive distributor across Mainland China with the Company’s authorization.

Tonghua Dongbao is the largest supplier of insulin manufacturing and sales in China and pleased to participate in the subscription of Bionime private equity ordinary shares. It is the recognition of Bionime's patented technology in blood glucose monitoring system, excellent products and the growth of diabetes care in China. The future integration of both advantages of insulin products and blood glucose monitoring system, look forward to the benefit of the vast number of Chinese diabetes (about 100 million population of patients), in response to this strategic cooperation may bring revenue growth.

About Bionime

Established in April 2003, BIONIME is specialized in the business of biotechnology and medical testing. BIONIME integrates top-tier expertise in medical science, chemistry, electronics and precision engineering to commercialize our patented noble metal, biosensor technology used in our meters and test strips. Today, BIONIME employs more than 650 people and operates 4 subsidiaries in Europe, the Americas, Australia and Asia. Our products have been shown to meet or exceed the highest standards of accuracy and precision in numerous independent studies published in leading international clinical journals. Bionime products are distributed worldwide and are available in all the major markets. For more information please visit our Web Site at www.bionime.com

About Tonghua Dongbao Pharmaceutical Co., Ltd.